Exchange | Jotup

2024 China-ASEAN Youth Culture Week and the 7th China-ASEAN Youth Symposium Successfully Held

Retrieved on:

Monday, April 1, 2024

Beijing, China--(Newsfile Corp. - March 31, 2024) - On March 31st, the 2024 China-ASEAN Youth Culture Week and the 7th China-ASEAN Youth Symposium, themed "Youth Practice in Mutual Learning and Exchange among Civilizations," were successfully concluded in Beijing.

Key Points:

Beijing, China--(Newsfile Corp. - March 31, 2024) - On March 31st, the 2024 China-ASEAN Youth Culture Week and the 7th China-ASEAN Youth Symposium, themed "Youth Practice in Mutual Learning and Exchange among Civilizations," were successfully concluded in Beijing.
Two roundtable forums focused on "How can China-ASEAN youth promote inter-cultural exchange in the region?"
and "How has emerging technology reshaped the social lives and experiences of youth in the ASEAN-China region?"
During the Citywalk, youth delegates embarked on a vibrant journey through Beijing, experiencing the unique charm of Chinese culture.

InspireSemi Announces Final Closing of Private Placement

Retrieved on:

Tuesday, April 9, 2024

Funding, Exchange, HPC, AI

Investors not resident in the United States were issued SV Units at a price per SV Unit of C$0.15.

Key Points:

Investors not resident in the United States were issued SV Units at a price per SV Unit of C$0.15.
Each whole SV Warrant is exercisable for one SV Share at a price per share of C$0.20.
Each whole PV Warrant is exercisable for one PV Share at a price per share of $20.00.
The Financing has been conditionally approved by the Exchange but remains subject to the receipt of final approval from the Exchange.

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Retrieved on:

Tuesday, April 9, 2024

ACRV, Exchange, Health, Intelligence, Patient, Neoplasm, Paradigm, Research, AP3, Sale, Security (finance), Prospectus, Investment, Therapy, PIPE, Jefferies, Machine learning, Medicine

Acrivon anticipates the gross proceeds from the oversubscribed PIPE to be approximately $130 million, before deducting fees to the placement agent and other offering expenses payable by the company.

Key Points:

Acrivon anticipates the gross proceeds from the oversubscribed PIPE to be approximately $130 million, before deducting fees to the placement agent and other offering expenses payable by the company.
The closing of the financing is expected to occur on April 11, 2024, subject to customary closing conditions.
“We are excited to announce this financing and thank our new and key existing investors who have shown their support for and confidence in Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
Jefferies acted as the exclusive placement agent in the private placement.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Katapult Holdings, Inc. - KPLT

Retrieved on:

Monday, April 8, 2024

Prior, Exchange, News, LLP, Bank statement, Annual report, Pomerantz

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Katapult Holdings, Inc. (“Katapult” or the “Company”) (NASDAQ: KPLT).

Key Points:

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Katapult Holdings, Inc. (“Katapult” or the “Company”) (NASDAQ: KPLT).
The investigation concerns whether Katapult and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ocugen, Inc. - OCGN

Retrieved on:

Monday, April 8, 2024

Prior, Exchange, News, LLP, Bank statement, Pomerantz, Audit

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN).

Key Points:

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN).
The investigation concerns whether Ocugen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
The Firm has recovered billions of dollars in damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II - KIND

Retrieved on:

Monday, April 8, 2024

Growth, Exchange, Form 10-Q, News, Ext, LLP, Complaint, ARPU, Pomerantz, Action Replay, Court, Cryptocurrency

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II (“Nextdoor” or the “Company”) (NYSE: KIND).

Key Points:

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II (“Nextdoor” or the “Company”) (NYSE: KIND).
Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Nextdoor and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Ibotta Announces Launch of Initial Public Offering

Retrieved on:

Monday, April 8, 2024

BofA Securities, JMP, UBS, Exchange, Goldman Sachs, Wells Fargo, Telephone, Sale, Attention, Prospectus, Ibotta, Bank of America, Evercore, Security (finance)

Ibotta will not receive any proceeds from the sale of shares by the selling stockholders.

Key Points:

Ibotta will not receive any proceeds from the sale of shares by the selling stockholders.
In addition, the underwriters will have a 30-day option to purchase up to an additional 843,750 shares of Class A common stock from the selling stockholders at the initial public offering price, less underwriting discounts and commissions.
The initial public offering price is estimated to be between $76.00 and $84.00 per share.
Citizens JMP, Needham & Company and Raymond James will act as co-managers for the proposed offering.

Cielo Announces Closing of Second Tranche of Private Placement of Convertible Debenture Units

Retrieved on:

Friday, April 5, 2024

CALGARY, Alberta, April 05, 2024 (GLOBE NEWSWIRE) -- Cielo Waste Solutions Corp. (TSXV:CMC; OTCQB:CWSFF) (“Cielo” or the “Company”), a renewable fuel company leveraging market ready licensed technology to produce low carbon fuel from wood by-products, is pleased to announce the closing of the second tranche (“Tranche 2”), for gross proceeds of C $1,480,000, of its previously announced non-brokered private placement offering of unsecured convertible debenture units of the Company (collectively, the "Convertible Debenture Units") at a price of C $1,000 per Convertible Debenture Unit for aggregate gross proceeds of up to C $5,000,000 (the "Private Placement"). The Company intends to continue to offer the Convertible Debenture Units on the same terms and close one or more subsequent tranches during the month of April 2024.

Key Points:

CALGARY, Alberta, April 05, 2024 (GLOBE NEWSWIRE) -- Cielo Waste Solutions Corp. (TSXV:CMC; OTCQB:CWSFF) (“Cielo” or the “Company”), a renewable fuel company leveraging market ready licensed technology to produce low carbon fuel from wood by-products, is pleased to announce the closing of the second tranche (“Tranche 2”), for gross proceeds of C $1,480,000, of its previously announced non-brokered private placement offering of unsecured convertible debenture units of the Company (collectively, the "Convertible Debenture Units") at a price of C $1,000 per Convertible Debenture Unit for aggregate gross proceeds of up to C $5,000,000 (the "Private Placement").
The Company intends to continue to offer the Convertible Debenture Units on the same terms and close one or more subsequent tranches during the month of April 2024.
Pursuant to the closing of Tranche 2, the Company issued 1,480 Convertible Debenture Units for gross proceeds of C $1,480,000, consisting of 1,480 Convertible Debentures and 3,700,000 Warrants.
As the Convertible Debentures will be unsecured debt obligations of the Company, each Convertible Debenture will rank subordinate to all secured debt obligations of the Company.

Cumulus Media Announces Further Extension of Expiration Time in Exchange Offer and Consent Solicitation Relating to 6.750% Senior Secured First-Lien Notes due 2026

Retrieved on:

Wednesday, April 3, 2024

Consent, Letter, CMLS, Exchange, Settlement date, Senior, Note, Exchange offer, Solicitation, Security (finance)

The Exchange Offer and Consent Solicitation will expire at the Further Extended Expiration Time, unless extended or terminated.

Key Points:

The Exchange Offer and Consent Solicitation will expire at the Further Extended Expiration Time, unless extended or terminated.
Questions or requests for assistance related to the Exchange Offer and Consent Solicitation or for additional copies of the Exchange Offer Documents may be directed to D.F.
You may also contact your broker, dealer, commercial bank, trust company or other nominee for assistance concerning the Exchange Offer and Consent Solicitation.
The Exchange Offer and Consent Solicitation is being made solely by the Offering Memorandum.

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

Retrieved on:

Wednesday, April 3, 2024

Clobetasol, Exchange, Infection, Acceleration, Refractive surgery, Inflammation, Annual general meeting, ASCRS, Patient, Private practice, Cataract, Society, Ophthalmology

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced that the company will be conducting demonstrations of its portfolio of commercial products at two upcoming ophthalmology medical meetings.

Key Points:

“Our presence at national medical and commercial meetings like these are key to elevating awareness of our continuum of office-based and surgical products,” stated Michael Rowe, Eyenovia’s Chief Executive Officer.
These meetings complement the efforts of our field sales force in amplifying the synergistic nature of our product portfolio as well as the many benefits conferred to doctors and patients by the Optejet device.
Eyenovia will also be demonstrating Avenova and reviewing now-approved data on clobetasol, which complements the company’s surgical suite of products.
The event features continuing education, keynote speakers, Exchange-only pricing from more than 100 vendors, and opportunities to network with colleagues.